MXCT - NASDAQ
MaxCyte, Inc.
$1.21
-0.22%MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
At a Glance
Live SnapshotMaxCyte, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
MaxCyte, Inc. Income Statement
MXCT • NASDAQ
| MaxCyte, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
33M | 38.6M | 41.3M | 44.3M | 33.9M | 26.2M | 21.6M | 16.7M | 14M | 12.3M | 9.3M | 7.2M | 6.8M | 5.1M | |
GROSS PROFIT | ||||||||||||||
(10.4M) | (7.1M) | (4.7M) | (5.1M) | (3.6M) | (2.8M) | (2.5M) | (1.8M) | (1.5M) | (1.3M) | (1M) | (957.5K) | (808.6K) | (830.4K) | |
22.6M | 31.5M | 36.5M | 39.2M | 30.2M | 23.4M | 19.1M | 14.8M | 12.5M | 11M | 8.3M | 6.2M | 6M | 4.2M | |
OPERATING INCOME | ||||||||||||||
(72.5M) | (82.7M) | (84.8M) | (66.5M) | (48.4M) | (34.5M) | (31.5M) | (23.3M) | (21.8M) | (13.7M) | (9M) | (7.5M) | (6.8M) | (6.2M) | |
(47M) | (56.4M) | (57M) | (44.5M) | (31.7M) | (15.7M) | (13.9M) | (12M) | (10.5M) | (9M) | (6M) | (5M) | (4.6M) | (4M) | |
(20.8M) | (22.2M) | (23.8M) | (19.5M) | (15.4M) | (17.7M) | (17.6M) | (11.2M) | (11.3M) | (4.7M) | (3M) | (2.5M) | (2.2M) | (2.2M) | |
-43.5M | -51.2M | -48.3M | -27.4M | -18.2M | -11.1M | -12.4M | -8.4M | -9.3M | -2.7M | -761.1K | -1.3M | -804.7K | -2M | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (126.9K) | (1M) | (825.6K) | (681.1K) | (614.6K) | (625.3K) | (637.8K) | (704.4K) | (561.3K) | (153.5K) | (61.7K) | |
7.3M | 10.1M | 10.4M | 3.8M | -893.6K | -759.7K | -475K | -444.3K | -625.3K | -637.8K | -704.4K | -561.3K | -153.5K | -25.9K | |
(4.6M) | (4.1M) | (4M) | (2.5M) | (1.3M) | (1M) | (0.0) | (0.0) | (0.0) | (15.7K) | (20K) | (0.0) | (0.0) | (0.0) | |
-1.1M | 10.1M | 10.4M | 3.8M | -893.6K | -759.7K | -475K | -444.3K | -625.3K | -622.1K | -684.4K | -561.3K | -153.5K | -25.9K | |
-44.6M | -41.1M | -37.9M | -23.6M | -19.1M | -11.8M | -12.9M | -8.9M | -9.9M | -3.3M | -1.4M | -1.8M | -958.2K | -2M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (681.1K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-44.6M | -41.1M | -37.9M | -23.6M | -19.1M | -11.8M | -13.6M | -8.9M | -9.9M | -3.3M | -1.4M | -1.8M | -958.2K | -2M |
SEC Filings
MXCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your MXCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.